Merck, Prof Combat Osteoporosis (The Harvard Crimson)

A Harvard immunologist’s research focused on developing new therapies for the treatment of osteoporosis has resulted in a lucrative deal with Merck & Co..

This entry was posted on Monday, April 14th, 2008 at 11:02 pm and is filed under Osteoporosis. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.